Featured Trial

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Study Identifier:

382-201-00001

ClinicalTrials.gov Identifier:

EudraCT Identifier:

N/A

Study Contact Information:

Recruiting

Type

Interventional

Study Drug

Drug: SEP-363856

Phase

Phase 2

Trial Dates

Nov 2022 - May 2025

Estimated Enrollment

900

Therapeutic Area

Depression

Study Locations

Location

Status

Location

For additional information regarding sites, contact 844-687-8522

New York, New York, United States, 10001

Status

Recruiting